Researcher
Erwin Dreesen
- Disciplines:Biomarker evaluation, Biopharmaceutics, Pharmacodynamics, Pharmacokinetics, Pharmacotherapy, Computational biomodelling and machine learning
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2021 → 30 Sep 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Oct 2019 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Sep 2014 → 30 Sep 2019
Projects
1 - 10 of 15
- Handling of social determinants in pharmacokinetics-pharmacodynamics analyses to enhance equity and inclusion in drug dosing in neonates, children, and adolescentsFrom4 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patientsFrom28 Aug 2023 → TodayFunding: FWO Strategic Basic Research Grant
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Pharmacodynamics models to bridge the gap between exposure and response to antimicrobial treatmentsFrom1 Oct 2021 → 30 Sep 2023Funding: BOF - projects
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Master protocol methodological pharmacometrics researchFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gastrointestinal physiology and drug disposition in geriatric patientsFrom5 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
31 - 40 of 97
- Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia(2022)
Authors: Matthias Gijsen, Johan Maertens, Katrien Lagrou, Stefanie Desmet, Erwin Dreesen, Willy Peetermans, Yves Debaveye, Isabel Spriet
- Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy(2022)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Marc Ferrante, Séverine Vermeire
Pages: 150 - + - Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases(2021)
Authors: Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, Marc Ferrante, Erwin Dreesen
Pages: 1455 - 1466 - Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates(2021)
Authors: Omar Elkayal, Karel Allegaert, Anne Smits, Erwin Dreesen
Pages: 3229 - 3236 - Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (vol 158, pg 2139, 2020)(2021)
Authors: Erwin Dreesen, Séverine Vermeire, Peter Bossuyt
Pages: 817 - 817 - Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes(2021)
Authors: Pieter Van Brantegem, Neel Deferm, Erwin Dreesen, Pieter Annaert
Pages: 20 - 32 - Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis(2021)
Authors: Ruben Faelens, Zhigang Wang, Paul Declerck, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
- The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases(2021)
Authors: Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, Debby Thomas, Séverine Vermeire, Marc Ferrante, Erwin Dreesen
Pages: 3776 - 3789 - Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model(2021)
Authors: Erwin Dreesen, Debby Thomas
Pages: 1587 - 1587 - Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics(2021)
Authors: Ruth Van Daele, Yves Debaveye, Robin Vos, Erwin Dreesen, Omar Elkayal, Pieter Vermeersch, Katrien Lagrou
Pages: 1111 - 1116